BRIEF published on 12/09/2025 at 18:35, 5 days 21 hours ago Theraclion submits Sonovein to the FDA after significant progress FDA Theraclion SONOVEIN Varicose Veins HIFU
BRIEF published on 12/09/2025 at 18:35, 5 days 21 hours ago Theraclion Submits Sonovein to FDA After Year of Key Achievements FDA Submission Clinical Evidence SONOVEIN Regulatory Achievements Varicose Vein Treatment
PRESS RELEASE published on 12/09/2025 at 18:30, 5 days 21 hours ago Inside Information / Other news releases Theraclion announces FDA submission of Sonovein following a year of regulatory and clinical achievements. Key milestones in Europe and China also reached Clinical Milestones FDA Submission Theraclion SONOVEIN Regulatory Achievements
BRIEF published on 10/29/2025 at 18:35, 1 month 16 days ago Theraclion Announces 2025 Half-Year Financial Results and Strategic Progress Financial Results Revenue Growth Market Expansion U.S. Study Certification Progress
PRESS RELEASE published on 10/29/2025 at 18:30, 1 month 16 days ago Inside Information / News release on accounts, results Theraclion reports successful pivotal study, CE certification, GB 9706.1-2020 certification; 89% revenue increase and 23% operating loss reduction in 2025 half-year results Revenue Increase Operating Loss Reduction CE Certification Pivotal Study Theraclion
BRIEF published on 10/21/2025 at 18:35, 1 month 24 days ago Theraclion obtains crucial certification in China Medical Theraclion SONOVEIN® Focused Ultrasound Chinese Certification
BRIEF published on 10/10/2025 at 18:35, 2 months 4 days ago Monthly publication of Theraclion voting rights Share Capital Voting Rights Investment Euronext Growth Theraclion
PRESS RELEASE published on 10/10/2025 at 18:30, 2 months 4 days ago Inside Information / Other news releases Theraclion provides monthly update on total voting rights and shares. The French MedTech company uses focused ultrasound for non-invasive treatment. CE-marked platform SONOVEIN® targets varicose veins Voting Rights Shares Theraclion SONOVEIN Focused Ultrasound
BRIEF published on 09/15/2025 at 18:35, 2 months 29 days ago Theraclion Successfully Completes Pivotal Study with 96.8% Occlusion Rate FDA Clinical Trial Theraclion SONOVEIN® Varicose Veins
PRESS RELEASE published on 09/15/2025 at 18:30, 2 months 29 days ago Inside Information / Other news releases Theraclion announces successful U.S. FDA pivotal study showing 96.8% occlusion rate with Sonovein® for varicose vein treatment. Results support potential U.S. market entry Theraclion SONOVEIN® U.S. FDA Study Varicose Vein Treatment Occlusion Rate
Published on 12/15/2025 at 15:00, 1 hour 9 minutes ago Kingfisher Reports Annual General Meeting Voting Results
Published on 12/15/2025 at 15:00, 1 hour 9 minutes ago Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Published on 12/15/2025 at 14:30, 1 hour 39 minutes ago Unusual Machines Congratulates Customers Selected for the Army's PBAS Tranche 1.1, Including Envision Technology and Strategic Logix
Published on 12/15/2025 at 14:00, 2 hours 9 minutes ago Dateline Delivers Further High-Grade Intercepts from North Pipe at Colosseum
Published on 12/15/2025 at 13:30, 2 hours 39 minutes ago Greenlane Announces Results of Annual Meeting of Stockholders, Canopy Growth Co Founder Bruce Linton Joins Greenlane's Board of Directors
Published on 12/15/2025 at 15:50, 18 minutes ago Original-Research: Cabka N.V. (von First Berlin Equity Research GmbH): Kaufen
Published on 12/15/2025 at 15:49, 19 minutes ago Mutares submits an irrevocable offer to acquire Venator Ultramarine Blue Pigments business from Venator France SAS
Published on 12/15/2025 at 15:45, 23 minutes ago Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated
Published on 12/15/2025 at 15:44, 24 minutes ago Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 12/15/2025 at 15:43, 25 minutes ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 12/15/2025 at 11:50, 4 hours 19 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of November 30, 2025
Published on 12/12/2025 at 18:00, 2 days 22 hours ago Disclosure of trading in own shares between November 24th and November 28th, 2025
Published on 12/11/2025 at 08:30, 4 days 7 hours ago Edenred and Daimler Truck join forces to accelerate the rollout of charging infrastructure for electric trucks in Europe
